75178-90-4 5-(N-叔丁氧羰基氨基)-1-戊醇

运输信息：常温运输。危险描述：非危险化学品，WGK Germany:3，F:10-21，Hazard Note:Irritant，海关编码:2921490090，存储类别:10 - 可燃性液体

5-(N-叔丁氧羰基氨基)-1-戊醇可作为有机合成中间体和医药中间体，主要可用于实验室研发过程和化工生产过程中。

医药; 有机合成

合成路线 1（75178-90-4）

• 步骤: 向含有5-氨基-1-戊醇（15.0g，145.4mmol）的水（140mL）溶液和饱和NaHCO₃水溶液（1.4mL）的1.0L单颈圆底烧瓶中加入二碳酸二叔丁酯（33.3g，152.7mmol）的THF（280mL）溶液；将混合物在室温下搅拌过夜，烧瓶通向大气；反应完成后，用饱和NaHCO₃水溶液（90mL）稀释，用EtOAc（400mL）萃取；分离有机层，用Na₂SO₄干燥，过滤，蒸发溶剂，得到产物。
• 条件: With sodium hydrogencarbonate In tetrahydrofuran; water at 20℃
• 产率: 98%
• 参考文献: [1] Synthesis, 1990, p. 366-368; [2] Journal of Medicinal Chemistry, 2018, vol. 61, #17, p. 7892-7901; [3] Tetrahedron Letters, 1992, vol. 33, #20, p. 2833-2836; [4] Carbohydrate Research, 1999, vol. 322, #3-4, p. 201-208; [5] Bioorganic and Medicinal Chemistry, 2008, vol. 16, #3, p. 1376-1392; [6] Patent: WO2016/27262, 2016, A1; [7] Patent: WO2015/17519, 2015, A1; [8] Patent: WO2016/118666, 2016, A1; [9] Patent: WO2016/118697, 2016, A1; [10] Patent: US2018/72711, 2018, A1; [11] Patent: US2018/99940, 2018, A1; [12] Journal of Medicinal Chemistry, 2007, vol. 50, #21, p. 5217-5226; [13] Bioconjugate Chemistry, 2018; [14] Patent: US5679708, 1997, A; [15] Angewandte Chemie - International Edition, 2012, vol. 51, #32, p. 8110-8113; [16] Tetrahedron, 1998, vol. 54, #28, p. 7955-7976; [17] Journal of the American Chemical Society, 2003, vol. 125, #51, p. 15935-15940; [18] Molecules, 2013, vol. 18, #11, p. 13957-13978; [19] Angewandte Chemie - International Edition, 2005, vol. 44, #15, p. 2275-2279; [20] Patent: WO2013/116682, 2013, A1; [21] Journal of Organic Chemistry, 1983, vol. 48, p. 24; [22] Analytical Chemistry, 1998, vol. 70, #8, p. [d]1629-1638; [23] Organic and Biomolecular Chemistry, 2011, vol. 9, #11, p. 4108-4115; [24] Beilstein Journal of Organic Chemistry, 2013, vol. 9, p. 15-25; [25] Journal of Materials Chemistry B, 2014, vol. 2, #10, p. 1344-1353; [26] Journal of Medicinal Chemistry, 2014, vol. 57, #11, p. 4924-4939; [27] European Journal of Medicinal Chemistry, 2014, vol. 82, p. 16-35; [28] Chemistry - A European Journal, 2016, vol. 22, #9, p. 3009-3018; [29] Journal of Medicinal Chemistry, 2014, vol. 57, #22, p. 9673-9686; [30] Chemistry - A European Journal, 2013, vol. 19, #5, p. 1762-1768; [31] Journal of the American Chemical Society, 2013, vol. 135, #17, p. 6396-6398; [32] Advanced Synthesis and Catalysis, 2014, vol. 356, #10, p. 2321-2329; [33] Bioorganic and Medicinal Chemistry, 2013, vol. 21, #14, p. 4351-4357; [34] Organic Letters, 2015, vol. 17, #24, p. 6054-6057; [35] Journal of Medicinal Chemistry, 2015, vol. 58, #13, p. 5287-5307; [36] Tetrahedron Letters, 1996, vol. 37, #19, p. 3379-3382; [37] Journal of the American Chemical Society, 1999, vol. 121, #4, p. 866-867; [38] Bioorganic and Medicinal Chemistry Letters, 2000, vol. 10, #11, p. 1253-1256; [39] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, #21, p. 4828-4832; [40] Bioorganic and Medicinal Chemistry, 2006, vol. 14, #23, p. 7671-7680; [41] Journal of the American Chemical Society, 2002, vol. 124, #29, p. 8584-8592; [42] Tetrahedron Letters, 2004, vol. 45, #38, p. 7081-7085; [43] Patent: US6884868, 2005, B1; [44] Chemistry Letters, 2011, vol. 40, #9, p. 959-961; [45] Organic Letters, 2014, vol. 16, #16, p. 4070-4073; [46] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, #2, p. 283-287; [47] Tetrahedron, 2017, vol. 73, #27-28, p. 3866-3877; [48] Journal of Medicinal Chemistry, 2017, vol. 60, #16, p. 7067-7083; [49] ChemMedChem, 2018, vol. 13, #18, p. 1957-1971